Compare Amgen, Inc. (AMGN) vs Barrick Gold Corp (B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Barrick Gold Corp — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Barrick Gold Corp trades at $36.35 (market cap $61.25B). The key difference: Amgen, Inc. is far larger — about 3.2× Barrick Gold Corp's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | B | |
|---|---|---|
Market Cap | $196.12B | $61.25B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $52.97 |
52-Week Low | $271.18 | $20.73 |
Enterprise Value | $241.41B | $58.85B |
Dividend Yield | 2.77% | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Barrick Mining (B) trades at $36.68, down 0.41% on the day, with a bearish technical signal but strong fundamentals. The company reported robust 2025 results with revenue of $16.96B and net income of $4.99B, beating earnings estimates in recent quarters. Analyst consensus is strongly bullish with a $51.80 price target, though technical indicators show near-term weakness with support at $36.
The stock presents a value opportunity with a low P/E of 10.07 and strong cash flow growth, but faces headwinds from gold price volatility and bearish momentum. Upside potential exists if Q2 2026 earnings meet or exceed expectations, while risks include commodity price swings and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
